Therapeutic mRNA cancer vaccine encoding patient-specific neoantigens to deliver transcripts to antigen-presenting cells, driving MHC I/II presentation and priming CD8+ and CD4+ T-cell responses.
Patient-specific neoantigen-encoding mRNA is delivered to antigen-presenting cells, where it is translated and processed for MHC I and II presentation, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells to drive adaptive antitumor immunity.
YES
INDIRECT
The mRNA vaccine primes neoantigen-specific CD8+ T cells; these T cells recognize neoantigen peptides presented on MHC I of tumor cells and kill them via perforin/granzyme and Fas–FasL pathways.
Recombinant humanized anti-EGFR monoclonal antibody that blocks EGFR signaling (MAPK/PI3K) and may induce ADCC.
Glycoengineered humanized anti-EGFR monoclonal antibody that binds the extracellular domain of EGFR, preventing ligand-induced activation and dimerization to block downstream MAPK/PI3K signaling and inhibit tumor cell proliferation; Fc optimization enhances antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing cells.
YES
DIRECT
Binds EGFR on target cells and engages Fcγ receptor–bearing effector cells (e.g., NK cells) to induce ADCC (and possibly ADCP), leading to lysis of EGFR+ cells; EGFR blockade mainly inhibits proliferation.
Autologous genetically modified TCR-engineered SPEAR T-cell therapy expressing an affinity-enhanced TCR specific for the MAGE-A4 peptide presented by HLA-A2 and co-expressing CD8αβ to enhance class I–restricted cytotoxicity; designed to recognize HLA-A2/MAGE-A4 on tumor cells and kill them.
Autologous T cells genetically modified to express an affinity-enhanced TCR specific for the MAGE-A4 peptide presented by HLA-A2 and co-express CD8alpha/beta; following infusion they recognize HLA-A2/MAGE-A4 on tumor cells and mediate class I-restricted cytotoxic killing.
YES
DIRECT
Engineered TCR T cells recognize the HLA-A2/MAGE-A4 peptide complex on target cells and kill them via CTL effector mechanisms, primarily perforin/granzyme-mediated apoptosis (and Fas–FasL).
Autologous genetically modified TCR-engineered SPEAR T-cell therapy expressing an affinity-enhanced TCR specific for the MAGE-A4 peptide presented by HLA-A2 and co-expressing CD8αβ to enhance class I–restricted cytotoxicity; designed to recognize HLA-A2/MAGE-A4 on tumor cells and kill them.
Autologous T cells genetically modified to express an affinity-enhanced TCR specific for the MAGE-A4 peptide presented by HLA-A2 and co-express CD8alpha/beta; following infusion they recognize HLA-A2/MAGE-A4 on tumor cells and mediate class I-restricted cytotoxic killing.
NO
INDIRECT
Killing requires recognition of the MAGE-A4 peptide presented by HLA-A2; engineered T cells then induce perforin/granzyme-mediated lysis. HLA-A2 expression alone is not sufficient for killing.
A human IgG1κ monoclonal antibody administered intravenously with FcRn-enhanced half-life that binds the “a” determinant on hepatitis B surface antigen (HBsAg). It neutralizes HBV virions and subviral particles, forms immune complexes to accelerate antigen clearance, engages Fcγ receptor–mediated effector functions (e.g., ADCC, phagocytosis), and lowers circulating HBsAg to mitigate T-cell exhaustion and potentially restore adaptive immune responses.
Human IgG1κ monoclonal antibody with FcRn-enhanced half-life that binds the “a” determinant of hepatitis B surface antigen (HBsAg). It neutralizes HBV virions and subviral particles and forms immune complexes that accelerate antigen clearance, while engaging Fcγ receptors to drive ADCC and phagocytosis. By lowering circulating HBsAg, it may reduce T-cell exhaustion and help restore HBV-specific adaptive immune responses.
YES
DIRECT
The IgG1 mAb binds HBsAg on HBV-infected hepatocytes and engages Fcγ receptors on NK cells/macrophages to trigger ADCC (and potentially ADCP), leading to killing of HBsAg-expressing cells; it also neutralizes free virions.